Deal facts
- Buyer
- CCP PAW 2 LIMITED
- Target
- ANIMALCARE GROUP PLC
- Deal value
- Not disclosed
- Announced
- 28 July 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United Kingdom
- Consideration
- cash
CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the target are based in the United Kingdom. The consideration for the acquisition involves a mix of cash and shares. This structure allows the acquiring entity to take the healthcare company out of public markets. The transaction represents a significant shift in the ownership structure of the business. It moves the company from a publicly listed status to private ownership under the control of CCP PAW 2 Limited. The healthcare sector is a key area of focus for this acquisition. The simultaneous announcement and completion dates suggest a streamlined process for finalising the deal. This rapid execution indicates strong alignment between the parties involved in the transaction. The move to private ownership may allow for different strategic approaches in the future.
The transaction has been successfully completed. Regulatory approvals and other necessary conditions were satisfied to finalise the acquisition. Animalcare Group Plc is now a privately held company. The management team continues to operate the business under the new ownership structure. This change marks the end of the company's time as a public entity. The deal closes a chapter in the company's corporate history. Future developments will be driven by the private owners. The healthcare sector remains a vital part of the UK economy. This acquisition highlights ongoing consolidation in the industry. The focus now shifts to operational integration and strategic planning. The company is expected to continue its existing operations without disruption. Stakeholders can expect updates on the new direction of the business. The completion of this deal is a significant milestone for all involved parties.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
2 updates- Scheme effectiveClosed
Scheme of Arrangement becomes Effective
FOR IMMEDIATE RELEASE 30 July 2026 RECOMMENDED ACQUISITION of ANIMALCARE GROUP PLC ("Animalcare") by CCP PAW 2 LIMITED ("Bidco") (a wholly-owned subsidiary of funds managed or advised by Charterhouse Capital Partners LLP) implemented by way of a scheme of arrangement under Part 26 of the Companies Act 2006 Scheme of Arrangement becomes Effective Introduction
LSE RNS - Court sanction
Court Sanction of the Scheme
FOR IMMEDIATE RELEASE 28 July 2026 RECOMMENDED ACQUISITION of ANIMALCARE GROUP PLC ("Animalcare") by CCP PAW 2 LIMITED ("Bidco") (a wholly-owned subsidiary of funds managed or advised by Charterhouse Capital Partners LLP) to be implemented by way of a scheme of arrangement under Part 26 of the Companies Act 2006 Court Sanction of the Scheme Introduction O
LSE RNS
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.
Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…
- Buyer
- Trafalgar Asset Management, LLC
- Target
- The Greater Cannabis Company, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.
Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…
- Buyer
- Hanmi Pharmaceuticals Co. Ltd.
- Target
- Aptose Biosciences Inc.
- Deal value
- USD 3,466,470
- Deal type
- going private
GlaxoSmithKline LLC to acquire Nuvalent, Inc.
GlaxoSmithKline LLC has agreed to acquire Nuvalent, Inc. in a going private transaction. The deal was announced on 9 June 2026 and completed on 15 July 2026. The conside…
- Buyer
- GlaxoSmithKline LLC
- Target
- Nuvalent, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
FONAR, LLC to acquire FONAR Corporation
FONAR, LLC has agreed to acquire FONAR Corporation in a going private transaction completed on 3 June 2026. The deal involves the purchase of the US-based healthcare com…
- Buyer
- FONAR, LLC
- Target
- FONAR Corporation
- Deal value
- Not disclosed
- Deal type
- going private
Zydus Worldwide DMCC to acquire Assertio Holdings, Inc.
Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, wa…
- Buyer
- Zydus Worldwide DMCC
- Target
- Assertio Holdings, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
CCP PAW 2 LIMITED
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive